Cg Oncology Inc (CGON) Stock Price, Quote & News

Company Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC p...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 409 3700

Website: cgoncology.com

Address:

400 Spectrum Center Drive, Suite 2040, Irvine, United States

pat_soons_shlong Oct. 23 at 6:02 PM

$CGON what do you guys think of the current valuation? I just closed out of my position for a 55% gain, but id like to understand your guys perspective This is not my main stock and I don’t have the time for an intricate deep dive on more than a couple of my positions

0 · Reply

Buy_SoFi Oct. 23 at 5:04 PM

$TLTFF $MRK $IBRX $CGON Potential NASDAQ listing rumored/expected? ---> $TLTFF

0 · Reply

Buy_SoFi Oct. 23 at 5:03 PM

$TLTFF $MRK $IBRX $CGON NMIBC Phase II study about to complete enrolment. AMAZING numbers! (Potential FDA Accelerated Approval) ---> $TLTFF

0 · Reply

Jarra123 Oct. 10 at 3:11 PM

$CGON new competitor approaching with completed phase two, fast track for neoadjuvant therapy https://hamletbiopharma.com/hamlet-biopharma-announces-the-completion-of-the-alpha1h-phase-ii-study-in-non-muscle-invasive-bladder-cancer/

0 · Reply

BEATOFtheMARKET Oct. 9 at 10:56 PM

9/26/25 list results $CGAU $CGEN $CGNX $CGON 🔥 Cycle Trading Signal plugged into AI 🔥 list

0 · Reply

dlhman2002 Oct. 9 at 2:05 PM

$CGON More large buys coming in today.

1 · Reply

autopilotcopytrader Oct. 8 at 3:50 PM

$CGON bought this morning premarket sold the rip yay :-) may reenter

0 · Reply

JarvisFlow Oct. 8 at 12:47 PM

Guggenheim has updated their rating for CG Oncology ( $CGON ) to Buy with a price target of 90.

0 · Reply

Grinding10 Oct. 7 at 5:48 PM

$CGON is this BLA ever going to get fucking submitted or what?

1 · Reply

Buy_SoFi Sep. 23 at 3:00 PM

$TLTFF Rutherin and Ruvidar are miracle compounds, making other compounds even more potent. Acquisition target in the coming 2-3 years, maybe sooner. $CGON $IBRX

0 · Reply

CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic?

Sep 9, 2025, 10:31 AM EDT - 6 weeks ago

CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 9:08 AM EDT - 6 weeks ago

CG Oncology Stock Signals Bullish Momentum Ahead

Sep 5, 2025, 7:00 AM EDT - 7 weeks ago

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

Sep 3, 2025, 8:00 AM EDT - 7 weeks ago

CG Oncology Completes Enrollment in PIVOT-006

Aug 8, 2025, 8:00 AM EDT - 2 months ago

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jun 23, 2025, 9:58 AM EDT - 4 months ago

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

Jun 5, 2025, 8:00 AM EDT - 5 months ago

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 13, 2025, 8:00 AM EDT - 5 months ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 28, 2025, 11:14 AM EDT - 6 months ago

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

Apr 26, 2025, 4:10 PM EDT - 6 months ago

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Apr 2, 2025, 12:32 PM EDT - 7 months ago

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Mar 24, 2025, 8:00 AM EDT - 7 months ago

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Feb 26, 2025, 8:00 AM EST - 8 months ago

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Dec 16, 2024, 4:05 PM EST - 11 months ago

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 2:09 PM EST - 11 months ago

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

Dec 12, 2024, 8:19 PM EST - 11 months ago

CG Oncology Announces Pricing of Public Offering

Dec 11, 2024, 6:17 AM EST - 11 months ago

CG Oncology Announces Proposed Public Offering

Dec 6, 2024, 1:18 PM EST - 11 months ago

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

Dec 6, 2024, 8:00 AM EST - 11 months ago

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Dec 5, 2024, 7:00 AM EST - 11 months ago

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Aug 30, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 10:34 AM EDT - 1 year ago

CG Oncology: Promising Data, But Looks Expensive

Aug 8, 2024, 8:23 AM EDT - 1 year ago

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jul 9, 2024, 9:19 AM EDT - 1 year ago

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

Jun 6, 2024, 12:14 PM EDT - 1 year ago

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

May 24, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 9, 2024, 8:00 AM EDT - 1 year ago

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 1:04 PM EDT - 1 year ago

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

May 3, 2024, 11:23 AM EDT - 1 year ago

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Apr 26, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Apr 24, 2024, 10:00 AM EDT - 1 year ago

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

Mar 28, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Feb 22, 2024, 8:55 AM EST - 1 year ago

Protara: A Bombed Out Biotech With A Very Positive Skew

TARA

Jan 30, 2024, 7:00 AM EST - 1 year ago

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 29, 2024, 8:14 AM EST - 1 year ago

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

BTSG

Jan 27, 2024, 1:30 AM EST - 1 year ago

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Jan 26, 2024, 11:50 AM EST - 1 year ago

Biotech's First IPO of 2024 Popped 96%. What It Means.

Jan 25, 2024, 2:20 PM EST - 1 year ago

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

Jan 25, 2024, 1:46 PM EST - 1 year ago

CG Oncology valued at $1.75 bln in strong market debut

Jan 25, 2024, 7:51 AM EST - 1 year ago

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

Jan 24, 2024, 7:10 PM EST - 1 year ago

CG Oncology Announces Pricing of Upsized Initial Public Offering

pat_soons_shlong Oct. 23 at 6:02 PM

0 · Reply

Buy_SoFi Oct. 23 at 5:04 PM

$TLTFF $MRK $IBRX $CGON Potential NASDAQ listing rumored/expected? ---> $TLTFF

0 · Reply

Buy_SoFi Oct. 23 at 5:03 PM

$TLTFF $MRK $IBRX $CGON NMIBC Phase II study about to complete enrolment. AMAZING numbers! (Potential FDA Accelerated Approval) ---> $TLTFF

0 · Reply

Jarra123 Oct. 10 at 3:11 PM

0 · Reply

BEATOFtheMARKET Oct. 9 at 10:56 PM

9/26/25 list results $CGAU $CGEN $CGNX $CGON 🔥 Cycle Trading Signal plugged into AI 🔥 list

0 · Reply

dlhman2002 Oct. 9 at 2:05 PM

$CGON More large buys coming in today.

1 · Reply

autopilotcopytrader Oct. 8 at 3:50 PM

$CGON bought this morning premarket sold the rip yay :-) may reenter

0 · Reply

JarvisFlow Oct. 8 at 12:47 PM

Guggenheim has updated their rating for CG Oncology ( $CGON ) to Buy with a price target of 90.

0 · Reply

Grinding10 Oct. 7 at 5:48 PM

$CGON is this BLA ever going to get fucking submitted or what?

1 · Reply

Buy_SoFi Sep. 23 at 3:00 PM

$TLTFF Rutherin and Ruvidar are miracle compounds, making other compounds even more potent. Acquisition target in the coming 2-3 years, maybe sooner. $CGON $IBRX

0 · Reply

Grinding10 Sep. 22 at 7:36 PM

$CGON guess we r back to the bullshit where it fades everyday again

0 · Reply

Buy_SoFi Sep. 22 at 5:22 PM

$TLTFF Rutherrin(R) Shown to Be 100 Times More Effective Than Radiation Alone in Preclinical Cancer Models $CGON $IBRX $MRK $JNJ https://theralase.com/theralase-to-present-groundbreaking-research-at-astro-2025/

2 · Reply

Mik21212 Sep. 19 at 7:30 PM

$CGON

0 · Reply

theflynews Sep. 19 at 3:21 PM

Biotech Alert: Searches spiking for these stocks today - $CGON - https://thefly.com/permalinks/entry.php/CGONid4200713?1758294347C38

0 · Reply

Grinding10 Sep. 19 at 2:51 PM

$CGON guess the drug stopped working

0 · Reply

RoundAssRousey Sep. 19 at 1:15 PM

$CGON steadily moving higher. picked this up at $25 on a tip from a buddy. Trial data looks good , price action looks good . Lets keeo it going!

0 · Reply

theflynews Sep. 18 at 4:07 PM

Biotech Alert: Searches spiking for these stocks today - $CGON - https://thefly.com/permalinks/entry.php/CGONid4200159?1758211035C38

0 · Reply

Grinding10 Sep. 18 at 8:27 AM

$CGON had a buyout a couple years ago; ISEE 3 months before FDA decision; No rumors no nothing but the stock was moving just like this for 2 weeks; 🤷‍♂️

0 · Reply

GMExAPE Sep. 17 at 10:05 PM

RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $LU $CGON $CORT $WGS $KC

0 · Reply

JarvisFlow Sep. 17 at 6:00 PM

Morgan Stanley has adjusted their stance on CG Oncology ( $CGON ), setting the rating to Overweight with a target price of 56 → 79.

0 · Reply

theflynews Sep. 17 at 3:49 PM

Biotech Alert: Searches spiking for these stocks today - $CGON - https://thefly.com/permalinks/entry.php/CGONid4199421?1758124081C38

0 · Reply

dlhman2002 Sep. 16 at 6:34 PM

$CGON Bullish September....

0 · Reply

Market Cap	3.20B
Revenue (ttm)	1.14M
Net Income (ttm)	-88.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7,722.81%
Debt to Equity Ratio	0.00

Volume	662,200
Avg Vol	951,136
Day's Range	N/A - N/A
Shares Out	76.25M
Stochastic %K	68%
Beta	1.31
Analysts	Strong Sell
Price Target	$68.08